The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.

The c-Fes protein-tyrosine kinase exhibits strong expression in myeloid hematopoietic cells. Previous studies have shown that Fes induces differentiation in the chronic myelogenous leukemia-derived cell line K-562, suggesting that the Fes signal for differentiation is dominant to the Bcr-Abl signal for transformation in these cells. In addition, Fes has been shown to associate with and phosphorylate Bcr on NH2-terminal sequences retained within Bcr-Abl. To determine whether Fes interacts directly with Bcr-Abl, kinase-inactive Bcr-Abl was coexpressed with Fes in 293T cells, and phosphorylation was assessed by anti-phosphotyrosine immunoblotting. Bcr-Abl was strongly phosphorylated by Fes under these conditions, suggestive of direct interaction. Similarly, tyrosine phosphorylation of kinase-inactive Fes was observed after coexpression with active Bcr-Abl. To test for the interaction of Fes with Bcr-Abl under physiological conditions, wild-type and kinase-defective Fes were stably expressed in the cytokine-dependent myeloid leukemia cell line, DAGM. Expression of either form of Fes alone did not affect the proliferation or interleukin 3 dependence of these cells. The DAGM/Fes cells were then infected with Bcr-Abl retroviruses, and their rates of cytokine-independent outgrowth were compared. Fes dramatically suppressed Bcr-Abl-induced DAGM cell outgrowth relative to a cell line expressing beta-galactosidase as a negative control. This effect required Fes tyrosine kinase activity, because the kinase-inactive form of Fes did not affect Bcr-Abl-induced cell outgrowth. The phosphotyrosine content of both wild-type and kinase-inactive Fes was strongly enhanced after coexpression with Bcr-Abl in DAGM cells, similar to the 293T result. Phosphorylation of wild-type Fes correlated with stimulation of Fes tyrosine kinase activity in the presence of Bcr-Abl. These results show that Fes and Bcr-Abl interact in myeloid cells, leading to Fes activation and suppression of Bcr-Abl-induced conversion to cytokine independence.

[1]  T. Smithgall,et al.  Regulation of c-Fes Tyrosine Kinase and Biological Activities by N-Terminal Coiled-Coil Oligomerization Domains , 1999, Molecular and Cellular Biology.

[2]  T. Smithgall,et al.  Tyrosine phosphorylation enhances the SH2 domain-binding activity of Bcr and inhibits Bcr interaction with 14-3-3 proteins. , 1999, Cellular signalling.

[3]  C. Sawyers Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[4]  G. Vairo,et al.  Expression of BCR – ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation , 1999, Oncogene.

[5]  G. Hannon,et al.  Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Smithgall,et al.  Fibroblast Transformation by Fps/Fes Tyrosine Kinases Requires Ras, Rac, and Cdc42 and Induces Extracellular Signal-regulated and c-Jun N-terminal Kinase Activation* , 1998, The Journal of Biological Chemistry.

[7]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[8]  T. Smithgall,et al.  Oligomerization of the Fes Tyrosine Kinase , 1997, The Journal of Biological Chemistry.

[9]  Mario Stevenson,et al.  SH3-mediated Hck Tyrosine Kinase Activation and Fibroblast Transformation by the Nef Protein of HIV-1* , 1997, The Journal of Biological Chemistry.

[10]  T. Smithgall,et al.  Co-expression with BCR Induces Activation of the FES Tyrosine Kinase and Phosphorylation of Specific N-terminal BCR Tyrosine Residues* , 1996, The Journal of Biological Chemistry.

[11]  O. Witte,et al.  BCR-ABL induces neurite-like structures and BCR lacking the SH2-binding domain induces cell rounding in PC12 cells. , 1996, Experimental cell research.

[12]  R. V. van Etten,et al.  P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.

[13]  C. Sawyers,et al.  The CRKL Adaptor Protein Transforms Fibroblasts and Functions in Transformation by the BCR-ABL Oncogene* , 1996, The Journal of Biological Chemistry.

[14]  T. Smithgall,et al.  Autophosphorylation of the Fes Tyrosine Kinase , 1996, The Journal of Biological Chemistry.

[15]  C. Sawyers,et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.

[16]  N. Heisterkamp,et al.  Inhibition of Bcr serine kinase by tyrosine phosphorylation , 1996, Molecular and cellular biology.

[17]  O. Witte,et al.  Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene , 1995, Cell.

[18]  A. Bahnson,et al.  Centrifugal enhancement of retroviral mediated gene transfer. , 1995, Journal of virological methods.

[19]  R. Jove,et al.  The Ras GTPase-activating Protein (GAP) Is an SH3 Domain-binding Protein and Substrate for the Src-related Tyrosine Kinase, Hck (*) , 1995, Journal of Biological Chemistry.

[20]  T. Hirano,et al.  Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association , 1995, The Journal of Biological Chemistry.

[21]  O. Witte,et al.  Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS , 1995, Molecular and cellular biology.

[22]  K. Izuhara,et al.  Interaction of the c-fes proto-oncogene product with the interleukin-4 receptor. , 1994, The Journal of biological chemistry.

[23]  J. Griffin,et al.  p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. , 1994, The Journal of biological chemistry.

[24]  T Pawson,et al.  Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.

[25]  J. Wang,et al.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins , 1993, Molecular and cellular biology.

[26]  Nanxin Li,et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.

[27]  R. Glazer,et al.  Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713). , 1993, Oncogene.

[28]  R. Glazer,et al.  Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells. , 1993, Biochemistry.

[29]  Y. Yazaki,et al.  Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells. , 1993, Blood.

[30]  K. Arai,et al.  c‐fps/fes protein‐tyrosine kinase is implicated in a signaling pathway triggered by granulocyte‐macrophage colony‐stimulating factor and interleukin‐3. , 1993, The EMBO journal.

[31]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[32]  J. Wang,et al.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins , 1991, Molecular and cellular biology.

[33]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[34]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[35]  G. Yu,et al.  K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation. , 1989, The Journal of biological chemistry.

[36]  F. McCormick,et al.  Baculovirus expression of functional P210 BCR-ABL oncogene product. , 1989, Oncogene.

[37]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Yu,et al.  Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells. , 1988, The Journal of biological chemistry.

[39]  N. Heisterkamp,et al.  Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia , 1987, Cell.

[40]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.

[41]  T. Pawson,et al.  Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein , 1985, Molecular and cellular biology.

[42]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[43]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[44]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[45]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[46]  C. Lozzio,et al.  A Multipotential Leukemia Cell Line (K-562) of Human Origin 1 , 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[47]  T. Smithgall,et al.  The c-Fes family of protein-tyrosine kinases. , 1998, Critical reviews in oncogenesis.

[48]  A. Gotoh,et al.  The function of BCR/ABL and related proto‐oncogenes , 1997, Current opinion in hematology.